Published in Vaccine Weekly, November 7th, 2001
M-Vax and O-Vax are being studied for the treatment of melanoma and ovarian cancer. In addition, the company has scheduled a meeting with the FDA to discuss issues surrounding the current hold and Avax's planned changes to its product and manufacturing processes.
David L. Tousley, chief operating officer of Avax stated, "We expected that the resolution of the clinical hold would require additional dialogue with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly